Cambrooke Foods, an Ayer, MA-based manufacturer of innovative clinical nutrition products for patients who require specialized “diet for life” therapies, closed a Series A financing.
The round, whose amount remained undisclosed, was led by Galen Partners.
The company intends to use the new capital to accelerate its organic growth and fund specific product-category acquisition opportunities. It plans to launch several new products this year and is actively assessing new in-licensing and product acquisition candidates.
Founded in 2000 by parents of two children with Phenylketonuria (“PKU”), David and Lynn Paolella, Cambrooke Foods has provided premium low protein foods and formula products to over 60,000 sufferers worldwide. Its BetterMilk™ is based on a proprietary formulation of glycomacropeptide (GMP) and licensed from the University of Wisconsin.